• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Abbott Declares 406th Consecutive Quarterly Dividend

    6/13/25 11:34:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email

    ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 59 cents per share.

    This marks the 406th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025.

    Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.

    About Abbott:

    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

    Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

    Cision View original content:https://www.prnewswire.com/news-releases/abbott-declares-406th-consecutive-quarterly-dividend-302481276.html

    SOURCE Abbott

    Get the next $ABT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    6/16/2025$143.00Market Perform
    Leerink Partners
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    5/30/2023$112.00Overweight → Equal-Weight
    Morgan Stanley
    4/20/2023$125.00 → $127.00Overweight
    Barclays
    More analyst ratings

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blount Sally E. sold $337,116 worth of Common shares without par value (2,600 units at $129.66), decreasing direct ownership by 7% to 34,058 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      5/2/25 5:04:05 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Stratton John G was granted 1,635 units of Common shares without par value, increasing direct ownership by 9% to 19,033 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:30:29 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Starks Daniel J was granted 1,635 units of Common shares without par value, increasing direct ownership by 0.02% to 6,728,817 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:22:08 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Abbott Labs with a new price target

      Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

      6/16/25 8:17:39 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Abbott Labs with a new price target

      Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00

      10/8/24 7:11:39 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Abbott Labs with a new price target

      Piper Sandler initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $131.00

      9/19/24 7:31:59 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier

      Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reported significantly improved health status.Abbott's Healthy Food Rx community-focused "food is medicine" program provides home-delivered healthy food boxes and nutrition education in Stockton, Calif., where 60% of the population has diabetes or pre-diabetes.CHICAGO, June 20, 2025 /PRNewswire/ -- Late-breaking research presented at the American Diabetes Association's 85th Scientific Sessions showed that Abbott's (NYSE:ABT) Healthy Food Rx "food is medicine" program helped people living with diabetes

      6/20/25 7:30:00 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Receives Health Canada Authorization for Whole Blood Rapid Test to Help Assess Suspected Concussions

      The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussionThe test produces lab-quality results in 15 minutesClinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency roomThe test can be used to help evaluate patients up to 24 hours after injuryMISSISSAUGA, ON, June 16, 2025 /CNW/ -- Abbott (NYSE:ABT) announced today that Health Canada has approved the company's i-STAT TBI test cartridge for use with whole blood, helping clinicians to assess suspected concussio

      6/16/25 8:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Declares 406th Consecutive Quarterly Dividend

      ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 406th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio

      6/13/25 11:34:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care